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PREFACE 
In thlq pRpe~, ~n Pttempt is mAde to nre9ent the 
subject of dlcum~rol in Pll its A~pect~. There is still 
much wo~k to be done And m~mv aAns in our l<nowledr:re of 
of this ~~ent And its Actions. The liter~ture AVAileble 
to tbe ttme of wri tinc:r hAs been surveved And frorn it 
the hi story, chemt stry, nhArmAcoloc:rv, toxicolorzy, and 
therApeutic nrlnciples of dicurnArol elAbor~:~ted and 
presented. 
DICUMAROL 
INTRODUCTION 
~ The occurrence of a new hemorrhagic disease of cattle was reported in 
1921 by Schofield (51) in Canada and Roderick (52) in this country. It 
was found that all the cattle which came down with this hemorrhagic disease 
had eaten spoiled sweet clover hay of the Melilotus variety. Animals that 
were apparently quite healtr,were reported as dying within a few hours after 
the operation of dehorning. In less acute cases the cattle showed a rapid 
pulse, blanching of the mucus membranes, dullness, quietness and were able 
to take a little food even up to death. 
·According to Pamrnel's book on poisonous plants, the statement is rmde 
that the sweet clovers contain the substance cumarin Cg HsO, ani that the 
sweet clover is suspected of being poisonous in Europe. This was a rmtter 
of great concern to the cattle raisers since the sweet clover had been 
imported because it was recognized as a farm crop of great value. It was 
chemically and physically beneficial to the soil, and was very economical 
and easy to handle. 
Schofield (51) supposed that a powerful poison was most likely developed 
in the clover by microbic activity and that massive hemorrhage most likely 
results from a rupture in a small bloodvessel. Roderick (52), however, 
showed that the hemorrhage was due to a gradual progressive diminution in 
the prothrombin of the blood causing delayed coagulation time. Quick (34) 
in 1937 confirmed these findings of Roderick. 
It was recognized by Schofield that the disease would be controlled by 
the withdrawal of the spoiled sweet clover hay and by the injection of blood 
serum freshly drawn from normal cattle. 
• 
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EXTRACTION 
Many efforts had been made tG extract the causative agent from spoiled 
~ sweet clover. Schofield (51} attempted to prepare concentrates by extract! 
with water but without definite findings. Roderick and Schalk also tried 
by means of water without success. They also tried extraction with 95% II 
acid but without any results. Campbell, ethanol, ethyl ether, and 1% acetic 
Roberts, Smith, and Link (50) found that the hemorrhagic agent was insoluble 
in petroleum ether, ethyl ether, ethanol, acetone, dioxane, water and 
:-'aqueous acid. On the other hand, dilute NaOH effected the solution of the 
hemorrhagic principle. These men were able to use this method of extraction 
which yielded much higher activity than the original hay. A bluish-green 
ether solution was obtained. Upon removal of the ether, a green residue 
resulted. This concentrate showed a physiological activity equivalent to 
150 tines that of the original hay. Steps in the concentration of the 
hemormagic agent are given in Table I after Link (50). 
--------------· -=== 
TABLE I 
Steps in Concentration of the Hemorrhagic Agent: 
Spoiled sweet clover hay 
l 
1. Extract with n-pentane 
. .... -- ___ j 
............. ----··----:{. 
(Residue) 
....v-----·· --· --···--·--·-······· 
Extract (discard) 
2. Steep in water48 hrs., ph 1-2 
t --------------------------------- t Filter 
Filtrate (discard) 3. Steep in water 48 hrs., ph 11-
4. Adjust to ph 3.0, filter 
Filtrate (discard) (Resrdue} 
5. Extract with 95% ethanol; 
r------·------------------li, filter 
Residue (discard) (Filtrate) 
-!, 
Filtrate (discard) 
6. Remove ET OH at 30° 
7. Dissolve residue in 0.5% 
NaOH; adjust ph to 3.0; 
Filter 
. -· --·-t 
(Ppt.) 
8. Dissolve in methanol; ppt. 
with ethyl ether; filter. 
r-· -· ........ ---------- ·-·--·-------·-------- -------{ 
Ppt • (discard) 
~--
Water layer and insoluble ppt. 
(discard) 
(Filtrate) 
9. Remove solvent; dissolve resi-
due in 0.5% NaOH; adjust ph 
to 3.0; extract with ethyl 
ether. ··-···-i 
Ether solution 
activity 200 x original hay 
(minimum) 
3. 
4. 
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ISOLATION 
Campbell and Link (30) in 1940-41 were able to isolate the hemorrhagic 
agent in spoiled sweet clover hay (Melilotus alba) in a pure state from 
experimentally produced spoiled hays as well as from hays that kii1ed 
cattle in agricultural practice. 
.,. 
The substance has the empirical formula C19H12o6 and is 3, 3 -
methylene-bis (4 - hydroxycoumarin) and has the structural formula: 
0 
II 
0 
I J 
It has a melting point of 288-289° in the pure state and is optically 
inactive, has two acidic hydroxyls in the molecule, the pure substance hav 
ing an acidity between that of the phenols and the carboxylic acids. In 
the pure state, the substance has a low solubility in ordinary organic sol-
vents, is insoluble in acid rredia, but readily oolub1e (by salt fonnation) 
in basic solvents and dilute alkali. It cannot be characterized or identi-
fied on the basis of its behavior towards the usual identification reagents 
Campbell and Link found that 1.5 mg. of the crystalline hemorrhagic agent 
caused approximtely the same reduction in the prothrombin level or 
activity of the plasma of standardized susceptible rabbits in 40 hours as 
50 gm. of the standard spoiled hay sample. They showed that spoiled sweet 
clover hays produced experimentally from I~lilotus alba and other varieties 
contain approximately 0.003% of the hemorrhagic agent on the dry substance 
basis. 
5. 
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S'YN'IHllSIS 
After successfully isolating the hemorrhagic agent from the sweet clove 
hay, Link and his co-workers (31) set about to prepare the hemorrhagic agen 
synthetically. They had no difficulty whatsoever in synthesizing a product 
with a melting point in exact agreeiJEnt with that of the pure naturally 
occurring hemorrhagic agent, 288-289° c. 
"Other physical properties, crystal habit, limited solubility in the 
common solvents, and the absorption spectrum of the synthetic product were 
found to be identical with the naturally occurring substance. The cor-
responding derivatives prepared from both the natural and the synthetic 
material were recovered on degradation.• 
When the synthetic praiuct was fed to standardized assay rabbits at 
the levels previously used for the natural substance, a comparable reductio 
in prothrombin level was observed. Continued feeding of the synthetic 
product to rabbits, rats, guinea pigs, and dogs produced the fatal 
hemorrhages characteristic of the sweet clover disease. 
According to Link wthe elucidation of the structure of the hemorrhagic 
agent as 3, 3/- methylene-bis (4 hydroxycoumarin) suggests that the biolog-
ical synthesis durin~ spoilage involves an oxidation of the coumarin to 
4 - hydroxycoumarin followed Qy coupling with formaldehyde, 
~~" ex~~  _j H Oxidati~n ~ g H 
o o -o- "o 
as seen below:" 
+ CH2 0 
Coumarin 4 - Hydroxycoumarin Formaldehyde 
OH 
H reX) C-C 
H I 
c . 
,,-.............. 0 / 
0 
3, 3' - Methylene-bis (4 - Hydroxycoumarin) 
The capacity to induce the hypoprothrombinemia characteristic of the 
hemorrhagic sweet clover disease is not restricted to the compound found 
in nature since over 40 compounds with this tendency have been prepared. 
The term ~icumarol is used to represent the dicoumarin 3-3,....- methylene-bis 
(4- hydroxycoumarin). 
NATURE .~D MECHANISM OF ACTION 
Dicumarol, 3, 3- methylene-bis (4- hydroxycoumarin), is tbe active 
agent of the spoiled sweet clover which was isolated and synthesized by 
Link, Campbell and their co-workers as stated previously. Link (70) showed 
that the addition of any radicle to any part of the molecule of dicumarol 
leads to a lowered anticoagulant activity. They shONed also that the 
greater the change, the greater was the loss in activity as is seen in the 
following table: 
• 
H H 
0 0 
~. H ,~ 
~;-LV 
H 
o o? . 
rl~.-R 
Wo 
R 
-
-CH3 
-OH 
-BR 
-BENZJJ 
ACETYL 
SALIC'YLYL 
HEPI'ANOYL 
TRIMETHYLACETY"L 
METHYL 
-CH3 
-CH2 CH2 CH3 
-CH2 CH2 CH2 CH2 CH3 
- cs% 
-H 
• CH2 ~ 
- (CH2) ·. 4 CH3 
-(CH2)15 0% 
Activity 
0 
0 
0 
0 
1/30 
1/30 
0 
0 
1/1000 
1/4 
1/12 
1/30 
1/200 
1/800 
1/2000 
1/400 
1/80 
6. 
.f 
Link also showed that if the fundamental 4 - hydroxycoumarin were not 
present, complete loss in activity resulted. The following table (70) 
f' shows the changes in anticoagulant activity by removal of any group(s): 
3, 3 -Methylene-biB (coumarin) 
3, 3 -Methylene-bis (4-Hydroxy-
6-Methyl-d-pyrone) 
(Benzine rings la eking) 
Methylenebis (indanedione} 
(Lactone oxygens lacking) 
1, 3 - Disalicylylpropane 
(Carboxyl groups lacking} 
Inactive 
Inactive 
Inactive 
Inactive 
7. 
Dicumarol is not affected by the digestive processes and is therefore 
given orally. Absorption of the drug OCCtu'S in the smll intestine. In 
the conferences on therapy of the N.Y. State Medical Society (20) it was 
mentioned that achlorhydria affects the absorption of dicumarol, the 
drug not being as quickly absorbed when gastric acidity is low or absent. 
After the absorption of dicumarol from the small intestine, the sequence 
of events in relation to its action in the body is still quite vague. 
Roderick (52) showed that a gradual progressive diminution in the 
prothrombin of the blood explains the delayed coagulation and leads to the 
hemorrhagic tendency as seen in the sweet clover disease of cattle. But 
how did dicumarol actually cause a decrease in the prothrombin of the 
blood? A brief study of the mechanism of clotting might throw some light 
on the possibilities. Following is a simplified representation of the 
clotting Ill9<!hanism {63): 
Vitamin K + 
1) Fat soluble 
Protein Synthesized l 
in liver to 
Prothrombin 
Present in plasma 
usually in large 2) Occurs in Food 
3) Synthesized by in-
testinal bacteria 
Prothrombin + Thromboplastin + 
1) In plasma 
2) A protein 
Thrombin + 
1) In platelets and 
tissue juice 
2) Probably also 
present in so:me 
form in plasma 
3) An enzyme 
Fibrinogen 
1) A protein 
2) Synthesized in 
liver 
3) Present in 
normal blood 
excess. 
Calcium --+-).Thrombin 
1) Ionized 1) In blocd 
in plasm 
2) Clinically 
never being 
so low as to 
cause fail-
ure of clot-
ting IJBchanism. 
Fibrin 
1) "Clots• 
s. 
Fibrin Mixed with 
+ 
Platelets Clot retraction 
(•syneresis•) 
Interruption of this chain of events at any point (either because 
of a deficiency, or of a counteracting substance) may lead to hemor-
rhage. 
Could dicumarol destroy or inactivate the prothrombin in the blood? 
Bingham and Meyer (40) showed that when dicumarol is added to drawn blood 
there is no change in prothrombin time. Thus dicU!Il3.rol has no direct 
effect upon the blood. Brinkhous (43) showed that the liver is necessary 
for prothrombin synthesis, and Howell (41) showed that a total hepatectomy 
in the dog is followed by a rapid fall in the concentration of prothrombin 
in the blood. Could dicUI!Brol then act as a specific liver toxin? 
Schofield (51) attached more significance to h:Ls findings af liver injury 
than to the alteration in the blood. However, the long period of dela~d 
coagulability of the blood, sonetines 4 - 6 weeks, is not consistent with 
the extent of visible injury to t:ts liver which has a high margin of 
safety. The studies of Bollman (9) on animals, Bingham, Meyer and 
Pohle (3, 21) on human beings plus those of Barker am V/augh (6) indicate 
that hepatic function as tested by the hippuric acid test of Q.uick, the 
cephalin - cholesterol flocculation test of Hanger, the cone entration af 
bilirubin in the serum, the icteric index, the Takata-ara, and the total 
protein of the blood, is not affected by dicumarol and that nG gross or 
microscopic changes in the liver were demonstrated. Others (7, 21) also 
were unable to show any specific! ty of dicumarol as a liver toxin. Such 
failure might easily be due to the insensitivity of the tests, since it 
is well known that considerable damge can occur without any detectable 
10. 
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In 1921 Foster and Whipple (64) showed. that tissue injury and 
inflammation exert a powerfUl stimulus upon fibrinogen production causing 
a prompt and notable increase in fibrin values. They showed that severe 
liver necrosis produced low fibrinogen values, whereas slight liver injury 
served as a stimulus for the production of fibrinogen. Roderick {52) in 
1931 showed that the fibrinogen was decreased at first but later returned 
to normal. His graphs show also that in several cases there is a slight 
rise in fibrinogen at the beginning of the feeding of the sweet clover 
hay. Ham and Curtis {45) confirmed these f indi:rg s and suggested that 
a failure of fibrinogen to increase above nonnal in instances of severe 
infection may be a poor prognostic sign and may s~gest the presenqe of 
significant liver damage even though clinical signs of liver d:is ease 
are lacking. These authors also suegest that dicumarol is toxic to the 
. ' 
liver. Irish and Jaques (11) were able to show a change in fibrinogen 
during the first 24 - 48 hours following the injection of di cmmrol which 
indicated that its action was immediate. This was also suggested for the 
effect of dicuma.rol on prothrombin, the lag in the latter response being 
ascribed to the time required for the circulating prothrombin to be 
used up. 
Roderick (18) studied the possibilities of an excess in antithrombin 
or a deficiency of calcium ions as a cause of the hemorrhagic tendency 
but his results showed that none of these were involved. 
A possible relationship to vitamin K was suggested by ~uick (34). 
He showed, however, that this was probably not so since ether extracted 
alfalfa meal appeared to be as effective as non-extracted alfalfa meal 
n ,[) in inhibiting the action of spoiled sweet clover. This finiing muld 
suggest that a fat-soluble vitamin Kwas not the material responsible 
for the protective action of alfalfa. Link and his associates (49) found 
that vitamin K counteracted the hypoprothrombinemia induced by the anti-
coagulant (as did Townsend and Mills (24)) whether given before the 
anticoagulant, with it, or 12 hours later. Complete protection against 
dicumarol was achieved only when an enormous dose of vitamin Kwas given. 
This suggests that the vitamin functioned primarily in stimulating 
recovery from the effects of the anticoagulant, possibly by increasing 
the rate of synthesis or activation of the prothrombin. HOJrever, many 
other authors {6, 7 ,19,20, 33, 36, 38) have shown that vitamin K is without 
effect. Overman, Stahmann at al (71) showed that one conmon structural 
feature of all the physiologically active compoun:ls studied is that only 
those which yield salicylic acid or an 0 - hydroxybenzoic acid derivative 
on degradation show anticoagulant action. Overman, therefore, tested 
the action of salicylic acid in vitamin K deficient rats and demonstrated 
a resultant temporary hypoprothrombinemia which was comparable to that 
produced by dicumarol. He showed that salicylic acid is 1/20 as active 
as dicumarol, but its action can be deter.mined earlier. However, he iS 
unable to arrive at any conclusion from these findings, relative to the 
mechanism of action of dicumarol. 
Sullivan, Gangsted, and Link (46) found that in vitamin 0 deficient 
guinea pigs there is a much greater susceptibility to the action of 
dieumarol in producing a hypoprothrombinemia and that the guinea Qigs 
succumb earlier than do normal ones. ThiS bas also been confirmed by 
Richards and Cortell (61) when they shONed that vitamin 0 in abundance 
decreased the susceptibility to the anticoagulant and therefore suggested 
11. 
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that adequate vitamin C levels are necessary for rapid prothrombin 
synthesis. However, many investigators (7, 18, 23, 25 and others) were 
unable to find any abnormality in the blood vessels of dicumarized 
animals or man. 
Vfe can see therefore, that a great deal of work must still be done 
before the mechanism of action of dicumarol is completely known. 
The effect ofthe admin:lstration of dicumarol upon the coa~lation 
time of blood measured in glass and lusteroid tubes was extremely variable 
as shown by Davidson and Macdonald (19). In general, hcwever, they shcwed 
that the coagulation time becana prolonged as the prothrombin concentra-
tion reached low levels rut there was no true plrallelism between the 
two. 
It was found by Spooner and .. Jar (4) that platelets play an import-
ant role in the process of coagulation as they are closely associated with 
the phenomenon of syneresis and their disintegration releases thromboplasti~. 
They found that in those conditions where thrombotic tendencies are increae~d 
there results an increased stickiness of platelets, also a simultaneous 
increase in platelets which were hyperadhesive. These workers found that 
dicumarol definitely decreased the adhesiveness of platelets. The 
prothrombin time, however, is prolonged significantly before the actual 
decrease in platelet adhesiveness can be detected. 
less is known about the destruction of dicwmrol in the body than 
is known a bout its action. Link a.nd his associates M. ve been the only 
authors to report on this. They were unable to detect dicUIIRrol in the 
urine of dogs after administration of large amounts, but suggest that the 
kidney mie;ht play an important role in its destruction. 
The necessity or 
dicumarol therapy has 
using other therapeutic agents while instituting 
brought up the subject of antagonistic and synergist~c 
action. First and of primary importance is the action of dicumro 1 and 
heparin. When a rapid decrease in the prothrombin time is desired heparin 
is given to decrease the prothrombin already formed vbile d icwm rol acts 
upon that which is being formed. Walker and Rhoads (39) fbund that the 
effect of heparin is enhanced by the administration of dicurrarol when 
given in fairly liberal amounts. They show that only one-half to one-thir 
the amount of heparin was required when dicumro 1 was used. However, 
Evans ( 32) , Bollman and Preston ( 9) as well as :t;,.e iffer and Sa in ( 8) 
demonstrated that the rate or disappearance of heparin from the blood and 
its effectiveness in decreastog blood coagulability were not materially 
different in dicumarized dogs and in norml animals. 
With the great use of the sulfa drugs and their importance it became 
necessary to determine their effect o~icumarol administration. Evans (32) 
Pfeiffer and Sain (8) showed that their was neither antagonistic nor 
synergistic action. Brambel and Lahar (1) treated diabetic and 
arteriosclerotic gangrene with chemotherapy to check invading organisms 
and dicumarol to prevent thrombosis of the blood vessels. No antagonism 
between the two diverse chemical agents was observed, "as long as a geed 
13. 
state and output of fluids was maintained" (1). ___.
1
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Dicuma.rol has been used along with digitalis therapy by deTakets ,// 
\ /" 
I 
-· 
Trump ani Gilbert (26), who founi that digitalis caused a change in the 
clotting mechanism, that it might be due to a thromboplastic property, I 
to a mobilization of prothrombin from the liver, or evan increased thrombin 
or fibrinogen. Thus digitalis opposes the action of dicumrol making large 
doses of dicuDB.ro 1 necessary for therapeutic effect. 
Dicumarol was introduced in 1941 by ~~yer, Bingham, and Pohle (65) 
"' at the Uni varsity of Wisconsin, and by Butt, Allen, and Bollman (66) at 
the Mayo Clinic for the prevention of thrombosis, especially postoperative!~. 
These men believed that dicumarol might be used effectively in place of 
heparin (which had been used as an anticoagulant successfully but had the 
disadvantage of being very expensive, of needing a continuous intravenous 
injection and the difficulty of maintaining a constant effect on coagula-
tion time). Both groups showed that dicUIIE.rol did depress the prothrombin 
concentration in man. Thus dicumarol was introduced as a possible useful 
therapeutic agent for the prevention of thrombosis, especially postoperative'"" 
ly. 
The value of anticoagulant therapy was known long before dicu.msro 1 
or heparin were discovered. For many :years, leeches were applied to 
patients suffering from phlebitis. The leeches were placed directly over 
the veins, where they secreted hirudin, an anticoagulant substance. 
Various workers have tried to purify the crude mterial on a commercial 
seale, but the expense is great- The results of the leech treatment were 
good, the psychic effect was bad. 
~ker, Nygaard, and Walters (55) studied 1665 cases of postoperative 
venous thrombosis and pulmonary embolism and found the following facts: 
That the majority of patients having thrombophlebitis postoperatively had 
it between the 9 - 14th day. Ten percent of the cases diagnosed as 
thrombophlebitis had multiple episodes with an interval averaging 4 - 9 
days between the first and last episode. Embolism occurred in the majority 
of cases from the seventh to the fourteenth day (whetrer fatal or non-fatal). 
14. 
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The interval between episodes of emboli (first to last episode) was less 
than four days in the majority of cases. About 60% of all cases having 
multiple emboli terminate in fatal embolism. The first episode of embol-
ism was fatal in 24.4% of all cases. The fatal embolic phenomenon was 
preceded by non-fatal emboli in 36%. On the basis of this dQta, the 
authors state the following probabilities from the standpoint of clinical 
diagnosis: "If a patient who has had an operation has non-fatal pulmonary 
embolism, he has slightly less than one chance in five of subsequent embol-
ism, fatal or non-fatal, and slightly less than one chance in two of some 
sort of subsequent thrombotic or embolic episode. If all fatal embolisms 
which were preceded by a clinically diagnosed non-fatal embolism could 
be prevented, the total number of the fatal embolisms would be reduced by 
more than a third." The following charts (56} sum up these facts: 
PostOp. pul. embolism: comparison according to number of episodes am 
fatality. 
No. 
_.1_ 
-
Pts. with one episode only: non-fatal 471 52.5 
Pts. with one episode only: fatal 219 24.4 
Pts. with more than one: non-fatal 83 9~2 
Pts. with more than one: fatal 124* 13.8 
897 100.0 
* or the 343 cases at fatal pul. embolism 124 (35.2%} were preceded by one 
or more episodes of non-fatal embolism. 
Pros.nosis of pts. who have had a non-fatal pul. embolism 
~ .JL Pts. with one episode of embolism only: no 
subsequent thrombosis 38 56.2 
• • • " " " • : subsequent 
thrombosis 90 13.3 
" 
with one or more subse. episodes of 
embolism: non-fatal 83 12.2 
" • • final episode: fatal 124 18.3 
-678 100.0 
15. 
It is evident from these results that a form of anticoagulation 
therapy seems to be indicated to prevent the formation of emboli and 
thrombosis and to prevent further extension of existant lesions since a 
formed thrombus acts like a foreign body and causes further growth by 
epposition (B). It should be pointed out that dicumarol does not affect 
the thrombus already formed. Thrombus formation seems to be increased 
by a combination of factors such as slowed venous circulation, increased 
tendency of blood to clot and injury to the intimal surface of vessels. 
Care against any one or all of these might be of extreme value. Dicumarol 
decreases the clotting tendency by decreasing the prothrombin production 
and thus the concentration. 
Many clinics have investigated the uses of dicumarol, and in general 
find it very effective. The Mayo Clinic (5, 68) has administered dicwmrol 
to 1000 surgical patients postoperatively to ~revent venous thrombosis 
and pulmonary embolism. "'n the entire series of 1000 cases there was 
only one death from pulmonary embolism and in this case ••••••• the 
dicumarol had been given for an insufficient length of ti:rre. A thrombotic 
teniency had already been demonstrated in 379 patients in that they bad 
had thrombosis or embolism, and on 438 abdominal hysterectomies, an 
operation in which the expacted incidence of thrombosis and embolism was 
4%, and of fatal embolism 0.7%. No embolisms developed in the cases in 
which dicumarol was given.• 
A group of 138 cases of thrombophlebitis were treated with d icumarol 
to prevent further extension and pulmonary embolism. An incidence of 
10.6% subsequent thrombophlebitis and 5.7% of subsequent fatal pulmonary 
embolism was expected without dicumarol therapy. However, there was no 
16. 
case of pulmonary embolism, fatal or non-fatal, and only 2.9% of subsequent 
thrombophlebitis. 
A history of thrombophlebitis or embolism previous to OI=Bration was 
encountered in 61 cases. These patients received dicurmrol beginning on 
the second postoperative day and in no case did embolism, fatal or non-
fatal develop. 
Another group of 180 cases had had non-fatal postoperetive pulmonary 
embolism and infarction. The risk of further thrombosis with or without 
embolism was high (43.8%) and the risk of a subsequent fate.l embolism was 
18.3% (55.) There was a 1.1% incidence of subsequent venous thrombosis, 
pulmonary embolism, or i~arction and 0.6% of a subsequent fatal pulmonary 
embolism. 
Another group of 183 patients at the Mayo Clinic were given dicumarol 
as a prophylaxis after various operations. They were felt to be increased 
risk for postoperative thrombosis and embolism and yet no thrombophlebitis 
or embolism developed in any of these cases. 
At the Lahey Clinic (2) Evans studied 46 patients with postoperative 
venous thrombosis who were treated with anticoagulation therapy (heparin 
am d icuma.rol) and who were candidates for pulmonary embolism, showing 
that there were no fatalities and only one recognizable recurrent benign 
pulmonary embolism. The clinic does not hesitate to employ venous section 
and ligation in patients with a history of multiple pulmonary emboli, 
postoperative or otherwise, but does advise a prolonged course of anti-
coagulation therapy after ligation whe~ there is a likelihood of continuing 
active phlebitis and formation of venous thrombi. 
Evans (32) found that postoperative pulmonary embolism was more apt 
17. 
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to arise from silent unrecognized areas of phlebothrombosis than from 
clinically recognized thrombophlebitis. EvaDS founi that patients over 
50 years of age with arteriosclerosis and obesity, when subjected to 
hyster~ctomy, cholecystectomy, l[kulicz resection, resection of carcinoma 
of the large bowel, prostatectomy or herniotomy, are the most likely 
candidates for venous thrombosis and pulmonary embolism. Thus it may be 
adVisable to advocate anticoagulant therapy under such conditions. The 
results of heparin and dicumarol were good in all but one case, a fatal 
pulmonary embolism. 
Zucker (16) treated 18 patients with dicumarol orally. Nine patients 
with thrombophlebitis were treated for an average of 14 days with good 
results. Zucker believed that the duration of the illness in these cases, 
many of which were severe, was shorter than would have been expected with-
out t])e use of dicumarol. No evidence of central extension of the 
thrombin was found once an adequate prothrombin time had been reached 
although in several cases peripheral exteDSion continued for several 
days. pisappearance of pain in the affected .area or pronounced diminution 
was observed in many cases at the tl.IIB when the level of hypoprothrombinemi 
had been reached. Zucker also treated a p3.tient with cavernous sinus 
thrombosis w1 th dicumarol and sulfadiazene. The patient's clinical course 
was downhill until dicumarol was started after which he improved rapidly. 
In the conferences on therapy of the New York State Medical Society (2 ) 
dicumarol therapy was felt to be very effective in mesenteric thrombosis, 
and was used successfully in four cases of coronary thrombosis. However, 
this was too small a series from which to draw any conclusions. •In 
thrombosis of a blood vessel, the mere existence of a thrombus may be less 
18. 
menacing than the deposit of additional mterial upon it and the later 
breaking off of portions of this mater! al to fo m emoo 11. In coronary 
occlusion, one of the chief dangers may be an extension of the existing 
thrombus and injury to the cardiac wall so that mural thrombi are formed 
well after the original coronary occlusion. 
Lam (54) at the Henry Ford Hospital treated 60 patients with dicumarol 
for postoperative pulmonary infarct, coronary occlusion and pulmonary 
infarct, prophylaxis postoperatively, and one case of phlebitis. Of 
these, two had a second and fatal embolism, giving a mortality rate of 
3.3% as compared with a 11.9% mortality rate without treatment at that 
hospital. 
Rhoads, Walker, and Panzer (62) treated three patients having sub-
acute bacterial endocarditis with dicumarol and sulfadiazene but felt 
the therapy a failure. Le Fevre (35) had also treated a patient with 
subacute bacterial endocarditis with sulfadiazene, heparin, and dicumarol 
am believed that the only effect was a possible decrease in the number 
of emboli thrown off. He therefore believed the benefit derived from 
its use was questionable. 
Brambel and Laher (1) directed their efforts to the use of dicumaro 1 
in trauma and various types of gangrene since war and increased industry 
were resulting in great numbers of injuries of this type. The authors 
divided their cases into three groups, namely ; (a) post-traumatic 
condition with associated gangrene following crush injury; (b) diabetic 
and arterioscleratic gangrene; (c) frostbite. They found that in trauma 
and gangrene there is injury to the endothelial lining of blood vessels, 
accelerated prothrombin clotting time, and liberation of excess 
• 
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thromboplastin by traumatized tissue, all of which favor thrombus forma-
tion and that there is mrked swelling which interferes with norml 
circulation and oxygenation of the tissues. Because of this enhanced 
coagulation mechanism, definite resistance to the effects of dicumarol 
were noted when compared with normal persons. In the cases presented by t se 
workers, it was thought that the loss of an appendage was highly probabl~ 
under ordinary conditions, since it has been shown that gangrene may readi 
develop in extremities 4 - 7 days after trauma which has resulted in 
lacerations and severe crushing injuries. With the use of dicumarol 
excellent results were obtained, no instance requiring a major amputation 
following a crush injury. These authors also treated a case of bilateral 
gangrene of the feet following prolonged exposure to cold. With dicumarol 
therapy the extension of the gangrene was checked and on the basis of 
previous experience the writers believe that gangrene wouldhave extended 
sufficiently to necessitate the amputation of both feet. 
Butsch (37) gave dicwmro 1 24-48 hours before operation in 23 patient 
for herniorrhaphy. There was no excessive oozing of blood or any difficul 
With hemoStJlSiS • Twenty-one wounds healsd primarily. But; SCh believed 
there was apparently enough thromboplastin liberated in the incised wound 
to promote reasonably satisfactory hemostasis after the wound is sutured. 
Smith and Allen (67) had shown in 1940 that the administration of 
thyroid extract served to increase the rate of blood flow. They alSo 
found that adrrdnistration of thyroid extract after operation, prevented 
the slowing of venous circulation which usually occurs after operation. 
Wakin, Chen, and Gatch (14) in 1945 set about ·to study whether the 
administration of thyroid extract had a synergistic effect with the pro-
oo. 
second day and dosage after that is controlled by daily determination of 
prothrombin time. 
Brambel and lahar (1) administered dicumarol in 300 mg. doses until 
the prothrombin time ranged between 30-35 seconds for undiluted plasma. 
They found that the average total amount required to maintain the pro-
thrombin time below 75% of normal was 1200 mg. in 8 days. When the pro-
thrombin time fell below 60% or full precipitously, the drug was dis-
continued. The prothrombin time may continue to drop as long as five days 
after the drug is discontinued. 
The desirable prothrombin tins fo.r anticoagulant therapy was detennim 
by Allen, Barker and Waugh (6), to be 35-60 seconds. They administer 
200 mg. on the third day if the prothrombin tine is less than 35 seconls. 
Wright and Prandoni (7) shewed that a sirgle lArge dose of 600 mg. 
produced less physiologic and definitely less tax:ic effects than total 
equivalent doses administered in portions of 100 ng. daily. This was 
previously noted in animals by Link and Associates and attributed to 
imperfect intestinal absorption since they found considerable quantities 
of the· dicumarol in the feces of animals given massive doses by mouth. 
Butt, Allen and Bollman (66) have given single doses of iooo mg. orally, 
apparently without resultant toxicity. An abnormally high environmental 
temperature, vitamin K de~icieney, inanition, hepatic or renal injury were 
shown to greatly exaggerate the effect of the drug. Link and his ~ssociate 
(31) also add dehydration and anacidity. Prandoni and Wright (25) say 
temperature ma1 increase effects but dehydration and anacidity are unlikely 
MOst of these cases showed normal acidity or even hyperacidity. 
23. 
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Wasserman and Stats (33) took a satisfactory response to dicumarol 
to be an increase in the clotting time of the Whole blood to 15-20 minutes 
and a fall in the prothrombin index of the plasma to between 30 and 50% 
of normal. At the same time, there must not be untoward toxic effect, 
that is, hemorrhagic manifestations. 
The dis odium salt has been given intravenously by Bingham and 
• 
Associates (21) who believe that 4-5 mg. per kilogram of body weight may 
be given with safety. There is the same lag tiim as oral administration. 
The only advantages of intravenous administration, therefore, would seem 
to be: (1) prevention of irregular effect owing to irregular absorption 
from the gastrointestinal tract am (2) use in instances in Which the 
oral route Gannot be used, for example, after operations on the gastro-
intestinal tract. 
Rhoads, Walker and Panzer (62) use dicumarol as a basic anticoagulant 
and then give intramuscular or intravenous injections of heparin at 8-12 
hour intervals. Injections of heparin by the intramuscular route give 
coagulation time values which are less erratic than w·hen the intravenous 
route is used. This"method penn.its prompt starting (especially when 
heparin is given intravenously in patients with pulmonary embolism). 
It requires considerably less heparin than when no dicumarol is used. 
The dicumarol can be kept at a basal level so that, should hemorrhage 
appear, the heparin effect could be counteracted with protamine. 
Thus from clinical reports, it appears that a practical and effective 
safe dosage schedule would be: 
First day- Detenn.ine prothrombin tilll3 for oontra-imications. If no!'!!'F..l 
give one dose of 200 to 300 mg. depending on the size and con'l.ition 
========t=========================================-=======----------
Second day - The prothrombin time is determined and if it is more than 
25% of normal, administer 100 mg. to 200 mg. of dicumarol. 
Third and each subsequent day - The drug is not administered until the 
result of the prothrombin time or activity for that day has been de-
termined. No dicUI!l9.rol is given on any day that the prothrombin activity 
is less than 25%. If the prothrombin activity is 25% or more, 100 mg. to 
200 mg. of the drug, determined by the patients previous response, are 
administered. 
In the event that the prothrombin activity becomes reduced below 
15%, the patient should be closely observed and at the first indication 
of bleeding, transfusions of fresh whole blood should be given, and 
repeated if necessary unt 11 the hemorrhage is controlled. With the first 
transfusion, a single, slow, intravenous injection of a large dose of 
a water-soluble preparation of vitamin K may be of value. In the event 
of such excessive hypoprothrombinemia, the patient should be carefully 
examined once or twice daily and prothrombin activity determined with 
equal frequency until the prothrombin activity returns within the 
desired therapeutic range. 
An elevation of prothrombin time by mans of dicumarol has been 
maintained in dogs for periods up to one year without evidence of 
untoward effects. A number of patients have been maintained on dicumarol 
therapy for periods of one to four months (3). Only rarely will pro-
tracted elevation of prothrombin tine be indicated or desired, and until 
more evidence is available prolonged administration should be limited 
to 4-6 weeks. 
'. 
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Treatment may be reinstituted if there is recurrence of intra-
vascular clotting in a patient who has had dicumarol therapy or a relapse 
after dicumarol is discontinued. A prothrombin time determination must 
be mde before a second course of dicumarol iS instituted. Treatment must 
be based on the percentage of prothrombin activity, the patients previous 
response to dicumarol and his general clinical condition when the subse-
quent course or courses are instituted. There is no indication that 
subsequent courses increase or decrease the sensitivity of the patient. 
Administration should therefore be based upon the same control factors 
that apply to the initial course of dicumarol. 
When dicumarol is discontinued, the elevated prothrombin tine slowly 
returns to normal in 2 to 10 days, depending on the duration of therapy 
and somewhat on the total dose administered. It is obvious that the 
patient be closely observed during this period. 
Ton ciTY 
It is well to emphasize that dicumarol is a hemorrhagic agent which 
may produce dangerous hemorrhage unless its administration is controlled 
rigidly. The amount of drug administered nmst depend on the prothrombin 
time. It has been shown by Bingham, Meyer, and Pohle {3) that dicumarol 
may be given for periods as long as 90 days without producing subjective 
symptoms or detectable undesirable objective findings. As much as 10 
grams of dicumarol has been administered over a 92 day period to a patient 
with thromboangiitis obliterans with symptomatic improvement and without 
detectable changes in liver function. 
Because of conside~dble individual variation in response, it is 
imperative that the prothrombin tilll3 and coagulation tin:B be measured 
not less than once a day. In dicwm.rol therapy the prothrombin concentre.t i 
is purposely altered for therapeutic effect, and unless carefully controlle 
severe or even fatal hemorrhage may result. 
A prothrombin ti:rre of less than 20% at normal has been IrBntiomd by 
several authors (2,9,23,33) as a level at 'lilich great care should be taken 
since the bleeding tendency is markedly incr~ased at this level. Evans (2) 
has shown that in rare cases bleeding may occur with a level as high as 
40% of normal. Wasserman and Stats (33) had one case in Which the pro-
thrombin time decreased to less than 10% of normal before any bleeding 
tendency became manifest. Therefore, the dangers of hemorrage cannot be 
determined before dicumarol therapy is begun on the basis of prothrombin 
~ time and each patient must be considered separately with close observation 
for signs of hemorrhage. 
Wright and Prandoni {7) examined various factors in an endeavor to 
2f1. 
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determine a possible cause for this variability. Analysis of the clinical 
and laboratory studies on their patients revealed: 
"1. That the incidence of toxic reactions was not significantly 
influenced by age or sax. 
2. That no significant correlation existed between malnutrition 
and frequency of toxic reactions. 
3. That no increase in capillary fragility was detected even in the 
hemorrhagic cases. 
4. That the incidence of either hypochlorhydria or achlorhydria was 
not significantly greater in the hemorrhagic group. 
5. That toxicity on the basis of retention due to renal dysfunction 
could not be established in the cases presenting hemorrhages." 
It is worthwhile, therefore, to see what manifestations of toxicity ha 
been noted in patients and to shew the pathology caused exrerimentally in 
laboratory animals. 
Zucker (16) founi that the earliest toxic signs in patients were meet 
frequently lassitude and general malaise with aching in the costovertebral 
angles. In spite of extensive hemorr~~ges in practically all parts of the 
body, and especially subcutaneous, in no instance was the capillary 
fragility found to be increased. He was unable to show toxicity on the 
basis of retention due to renal dysfunction, nor was he able to shaw any 
liver damage. In one patie.nt there occurred pettchial rashes over the 
shoulders and flanks. Several patients became nauseated with the first 
dose of dicumarol but with continued treatment had no further nausea. In 
a few patients he found transient microscopic hematuria. 
=--====tf=== 
Davidson and Macdonald (19) point out the development in a patient 
of a moderate normochromic normocytic anemia. 
Wasserman and Stats (33) described two cases with cramp-like abdominal 
pAins and mild diarrhea occuring a few hours after injection of the drug. 
Cahan (23) describes a case in which 2800 mg. of dicumarol were 
administered in 32 days, and due to the severe hypoprothrombinemia (20% of 
normal) bleeding began from the gums and purpuric manifestations became 
apparent. There was no increased capillary fragility nor decrease of 
platelets. 
Prandoni and Wright (25) recorded several patients showing hemorrhagic 
manifestations ·from dicurmrol therapy namely purpura, sublingual ecchymosis, 
conjunctival hemorrhage, gingival hemorrhage, epistaxis, hematuria, 
spontaneous bleeding at wound site, vertigo, hematemesis, weakness and 
lassitude. Vertigo and nausea probably indicated cerebral hemorrhage. 
One patient went into shock but recoverd with shock therapy. In spite of 
the great amounts of hemorrhage the author$ were unable to show increased 
capillary fragility in any case. 
Evans (32) has had two deaths from hemorrhage from the use of dicumarol 
in a series of 71 patients and 6 other hemorrhagic accidents. 
Townsend and Mills have shown in animals (24) that toxicity is indicate 
by listlessness, dyspnea, tachycardia, fever, and signs (eventually) of 
internal or external hemorrhage or both, followed by death. Postmortem 
examination on dogs revealed subcutaneous and intramuscular hemorrhage, 
t"\ and frequently gross hemorrhage into the gastrointestinal tract and pleural 
spaces, and multiple small hemorrhages in the lungs. No pathology was 
founi in the liver or kidneys except for srmll hemorrh8.ges and occasi onsl 
=-=--===tii== 
hydropic' degeneration which may be due to postmortem degeneration (25). 
The most constant feature was an apparent dilatation of capillaries, small 
arteries and veins. Other investigators (9, 21, 33, 36) also described· 
these same findings. Cahan (23) believes that the dilatation of the vessels! 
is a direct result of dicumarol toxicity due to an increased sensitivity of 
the blood vessels, especially the capillaries, to trauma. 
Many investigators (3, 9, 16, 23, 25, 33 and others) have sought to 
find an explanation for the a:rrl:iicoagulation effect on the basis of pathology 
in the liver or kidney as Schofield (51) clained to have founl in cattle 
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that died from the sweet clover disease. It has been shown quite conclusive y 
that dicunnrol has no effect on the functions of the liver or kidneys as 
determined by the many renal and hepatic function tests nor has it been 
shown by microscopic examination of the tissues. 
Ovennan, Field, and Link (49) found hemorrhage in .any part of the body 
with an adequate blood supply in the rat, but most commonly into the spinal 
canal. They found that even though there were no signs of hemorrhage the 
animals looked ill, the food intake and activity decreased, the hair 
became rough, and the animals felt cold to the touch. 
Schofield (51) mentioned a rapid pulse, blanching of the mucus membrane 
and the presence of subcutaneous swellings (this latter Roderick (52) was 
unable to find) in cattle with sweet clover disease. He mentions also that 
the animal is dull, quiet, takes.a little food even up to death, has 
definite joint stiffness, and commonly constipation. He noticed posterior 
paralysis·and cerebral symptoms occasionally in his cattle. Death was 
due only to the loss of blood in the body. 
At the conferences on therapy of the New York State Medical Society 
(20) it was shown that the erythrocytic sedimentation rate was very 
important because a sudden rise may indicate hemorrhage. Practically all 
the cases treated with dicUI!l!'trol that showed hemorrhage bad a marked 
increase in sedimentation rate. 
ANTIDOTE 
The transfusion of freshly drawn ci trated blood is the only means 
of i:rnm:ldiately counteracting an excessive dicumrol effect.· The effect 
of transfusion is apparently simply to supply prothrombin. H<l'lever, the 
reduced prothrombin ti:rm is only transient. Schofield (51) recognized 
this fact even in cattle w:1. th the sweet clover disease. Wassennan and 
Stats (33) do not believe that transfusions with fresh blood arrest the 
hemorrhagic tendency from dicumarol. 
Bank blood older than 96 hours is worthless according to Wright and 
Prandoni (?) probably due to reduction in prothrombin activity. 
Defibrinated blood which has been allowed to st~nd an hour had 
scarcely any influence in elevating the prothrombin of the plasma, as 
shown by ~uick (34). However, Roderick (52) had found that defibrinated 
blood controlled fairly effectively the acute hemorrhage of sweet clover 
disease. 
Link and his workers (49) found that the mxinrum effectiveness of 
dicumarol in rats was observed on diets low in vitamin K. Factors which 
counteracted the anticoagulant were present in a grain ration in fish meal 
and in alfalfa. They were able to extract the factor with petroleum ether 
am this could be reduced by irradiation of the extract. They also foum 
that vitamin K counteracted the hypoprothrombinemia induced by the anti-
3·1. 
coagulant (as did Townsend and Mills (24)) whether given before the anti-
coagulant, with it, or 12 hours later. Complete protection agaimt dicunBr 1 
was achieved only when an enormous dose of vitamin K was given. This 
suggests that the vitamin functiomd primarily in stimulating recCNery 
from the effects of the anticoagulant, possibly by increasing the rate at 
synthesis or activation of the prothrombin once the level in the blood has 
begun to fall. The Abbott laboratories have shown that the dicurnarol effec 
may be counteracted by the intravenous administration of very large doses 
of synthetic vitamin K-like preparations, e.g., Hykinone (~nadione 
bisulfite) in a dosage comparable to 40 mg. of I~nadione. The effect was 
apparent after several hours and is maximal in 18 hours. However, many 
other (6,7, 19, 20, 21, 33, 36, 38) authors have shown that vitamin K has 
no effect. From his experiments, ~uick {34) concluded that ether-extracted 
alfalfa meal appeared to be as effective as non-extracted alfalfa meal, a 
finding which would suggest that vitamin K, at least a fat-soluble form, 
was not the material responsible for the protective action of alfalfa. He 
suggested that the beneficial effect of alfalfa is exerted by supplying an 
accessory food factor required for prothrombin formation in the body. 
Roderick (52) had shown also that the addition of 5% dehydrated alfalf 
meal with the toxic hay helped to cent rol the sweet clover disease in 
cattle. Q.uick {57) sh"-lfed that the diet of rabbits is the important means 
for controlling or preventing the disease. Smith {44) however, believes 
that aJf'alfa exerts no influence, either prophylactic or curative on this 
disease. 
Wright,~nd Prandoni (25) attempted to show that vitamins C and P 
and nicetinic acid were of value in decreasing the prothrombin time but 
32. 
=====jit=="======-=-~=--=-=-=-=========-=-=-=--=-===------ ========= 
found them to be ineffective. 
The Parke Davis Laboratory has succeeded in preparing a purified 
solution of beef prothrombin and have fourd it to antagonize complstely 
the effects of dicumarol in dogs. Lozner and Macdonald (42) found that 
rabbit thrombin is of distinct value in the control of hemorrhage from 
small wounds. It accomplishes its results by the instantaneous precipi-
tation of fibrin. 
CONTRAINDIC.A.TIONS 
Dicumarol is a potent drug, its effects tend to be cumulative and 
prolonged. It should never be given unless the patient is in a hospital 
that provides facilities for daily prothrombin time determinations and 
facilities for the immediate transfusion of fresh blood of compatible type 
Absolute contraindications {5,6,8,12, and others} to the use of 
dicumarol are listed below: 
1. In subacute bacterial endocarditis. Probably adverse effects result 
from the increased t ardency of patients with subacute bacterial 
endocarditis to bleed from kidneys or into the br~in even when dicumar 
is not used. 
2. Renal insufficiency for any cause. The effect of dicumarol on 
prothrombin time is excessive in cases of renal insufficiency or in 
those in which adequate amounts of urine are not excreted. It should 
be used cautiously or not at all in these cases. 
3. Purpura of any type. 
4. Blood d~re.sia with tendency to bleeding. 
5. Existing ~rothrombin deficiency as might occur in hepatic disease, 
obstructive jaundice, and malnutrition. 
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6. Dicumarol is contraindicated in hemorrhagic diathesis except after 
splenectomy when it is felt certain that splenectomy is curative (2,32 • 
Relative contraindications or precautionary uses are: 
1. Existence of ulcerative or granulomatous lesions. 
2. Open wounds and a potentially bleeding surface, pregnancy and in the 
puerperium. 
3. Necessity for a second surgical operation within the next two~weekS. 
4. Vomiting due to gastric or intestinal obstruction, or the use of 
continuous gastric drainage. 
5. Operations on the brain or the spinal cord because of grave danger 
of hemorrhage at the site of operation. 
6. In cases in which the prothrombin time is already prolonged (vitamin 
K deficiency). 
?. Suspected or diagnosed vitamin C deficiency patients should be 
treated for it along with the administration of dicurmrol. 
8. In patients who are seriously ill,debilitated or cachetic. 
9. In febrile states because animal experiements indicate an inte~sified 
action in the presence of fever. 
In the group of cases where relative contraindications are present 
if pulmonary embolism or thrombophlebitis has developed, the risk of 
bleeding from the use of dicumarol may be definitely less than the 
risk of a subsequent episode of embolism. 
While the many hazards and our present limited knowledge of dicumarol 
prevent its extensive use, these problems are even now being attacked in 
laboratories and hospitals. Undoubtedly further research and clinical 
study of this agent will result in the developi~Bnt of a new therapeutic 
weapon which may well come to play an ~portant part in future medicine 
and surgery. 
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